

CITATION REPORT

List of articles citing

Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study

DOI: 10.1093/alcalc/37.5.504
Alcohol and Alcoholism, 2002, 37, 504-8.

Source: <https://exaly.com/paper-pdf/33572700/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
391	Baclofen suppresses motivation to consume alcohol in rats. <i>Psychopharmacology</i> , 2003 , 167, 221-4	4.7	99
390	Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. 2003 , 8, 1025-34		70
389	Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]. 2003 , 3, 16		54
388	Effect of Baclofen on Alcohol and Sucrose Self-Administration in Rats. 2003 , 27, 900-908		69
387	The neurobiology and control of anxious states. 2003 , 70, 83-244		748
386	Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. 2003 , 70, 105-8		92
385	Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. 2003 , 70, 85-91		99
384	Gamma-aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in <i>Drosophila</i> : adult RNA interference and pharmacological evidence. 2003 , 100, 5485-90		105
383	Suppression of alcohol delirium tremens by baclofen administration: a case report. 2003 , 26, 258-62		47
382	Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. <i>Neuropsychopharmacology</i> , 2004 , 29, 1050-62	8.7	276
381	Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. 2004 , 310, 952-63		181
380	Pharmacotherapy for alcohol-related disorders: what clinicians should know. 2004 , 12, 351-66		13
379	Drug addiction: the neurobiology of behaviour gone awry. 2004 , 5, 963-70		458
378	Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. 2004 , 28, 295-301		26
377	Baclofen for alcohol dependence: a preliminary open-label study. 2004 , 28, 1517-23		122
376	A role for GABA mechanisms in the motivational effects of alcohol. 2004 , 68, 1515-25		163
375	Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: potential pharmacotherapies for smoking cessation. 2004 , 1025, 491-503		52

374	Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. 2004 , 6, 343-61		12
373	Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. 2004 , 6, 403-14		106
372	The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. <i>Psychopharmacology</i> , 2004 , 172, 179-86	4-7	111
371	GABA(B) receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. <i>Psychopharmacology</i> , 2004 , 174, 358-66	4-7	65
370	Cocaine alters GABA(B)-mediated G-protein activation in the ventral tegmental area of female rats: modulation by estrogen. 2004 , 54, 30-6		13
369	GABA(B) receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization. 2004 , 308, 667-78		74
368	The Italian version of the Obsessive-Compulsive Drinking Scale: validation, comparison with the other versions, and difference between type 1- and type 2-like alcoholics. 2004 , 74, 187-95		84
367	Rats on the grog: novel pharmacotherapies for alcohol craving. 2004 , 29, 1341-57		33
366	Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports. 2005 , 28, 87-9		11
365	Anticonvulsants for alcohol withdrawal. 2005 , CD005064		31
364	Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats. 2005 , 36, 161-8		70
363	A better widget? Three lessons for improving addiction treatment from a meta-analytical study. <i>Addiction</i> , 2005 , 100, 742-50	4.6	38
362	Magnetic resonance spectroscopic studies of alcoholism: from heavy drinking to alcohol dependence and back again. 2005 , 29, 150-158		16
361	Safety and efficacy of GABAergic medications for treating alcoholism. 2005 , 29, 248-54		46
360	Factors mediating alcohol craving and relapse: stress, compulsivity, and genetics. 2005 , 29, 1325-33		3
359	Reducing effect of the positive allosteric modulators of the GABA(B) receptor, CGP7930 and GS39783, on alcohol intake in alcohol-preferring rats. 2005 , 525, 105-11		54
358	Critical assessment of how to study addiction and its treatment: human and non-human animal models. 2005 , 108, 18-58		182
357	Tolerance to baclofen's sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence. <i>Psychopharmacology</i> , 2005 , 178, 351-2	4-7	6

356	Development of medications for alcohol use disorders: recent advances and ongoing challenges. 2005 , 10, 323-43		30
355	Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. <i>Neuropsychopharmacology</i> , 2005 , 30, 119-28	8.7	96
354	The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. <i>Neuropsychopharmacology</i> , 2005 , 30, 2065-72	8.7	97
353	Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. <i>Alcohol and Alcoholism</i> , 2005 , 40, 147-50	3.5	193
352	How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. 2005 , 51, 59-66		96
351	Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. <i>CNS Drugs</i> , 2005 , 19, 873-96	6.7	94
350	Effect of the combination of naltrexone and baclofen, on acquisition of alcohol drinking behavior in alcohol-preferring rats. 2005 , 77, 87-91		16
349	Baclofen reduces fat intake under binge-type conditions. 2005 , 86, 176-84		62
348	Gamma-hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABA(B) receptor-mediated effects. 2005 , 131, 465-74		28
347	Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. 2005 , 30, 1209-24		127
346	The A-OCDS predicts both craving and alcohol cue reactivity in adolescent alcoholics. 2005 , 30, 1638-48		8
345	Cocaine-induced reinstatement requires endogenous stimulation of mu-opioid receptors in the ventral pallidum. 2005 , 25, 4512-20		121
344	Models for alcohol dependence: A clinical perspective. 2005 , 2, 313-318		3
343	Ethanol-induced conditioned place preference is expressed through a ventral tegmental area dependent mechanism. 2005 , 119, 213-23		104
342	Alcohol. 2006 , 173-241		11
341	Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. 2006 , 119, 276.e13-8		136
340	Bingeing rats: a model of intermittent excessive behavior?. 2006 , 46, 11-5		110
339	The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. 2006 , 50, 632-9		102

338	Phenotypic characterization of genetically selected Sardinian alcohol-preferring (sP) and -non-preferring (sNP) rats. 2006 , 11, 324-38		138
337	Clinical potential of GABAB receptor modulators. 2005 , 11, 317-34		46
336	Understanding and treating alcohol dependence. 2006 , 30, 567-84		9
335	Ethanol and sucrose seeking and consumption following repeated administration of the GABA(B) agonist baclofen in rats. 2006 , 30, 812-8		35
334	Baclofen: a new drug for the treatment of alcohol dependence. 2006 , 60, 1003-8		57
333	Neurotoxins and neurotoxicity mechanisms. An overview. 2006 , 10, 263-87		31
332	Baclofen-induced suppression of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats exposed to different alcohol concentrations. 2006 , 550, 123-6		38
331	Diazepam dose-dependently increases or decreases implicit priming of alcohol associations in problem drinkers. <i>Alcohol and Alcoholism</i> , 2006 , 41, 604-10	3.5	45
330	A role for GABA in alcohol dependence. 2006 , 54, 205-29		16
329	GABAB receptor association with the PDZ scaffold Mupp1 alters receptor stability and function. 2007 , 282, 4162-71		70
328	GABA(B) receptor-positive modulation decreases selective molecular and behavioral effects of cocaine. <i>Neuropsychopharmacology</i> , 2007 , 32, 388-98	8.7	57
327	Pharmacotherapy of dual substance abuse and dependence. <i>CNS Drugs</i> , 2007 , 21, 213-37	6.7	49
326	GABAergic medications for treating alcohol dependence. 2007 , 27, 539-40; author reply 540-2		1
325	Reply to Dr Caputo and Colleagues Regarding "GABAergic Medications for Treating Alcohol Dependence". 2007 , 27, 540-542		
324	Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. 2007 , 27, 319-20		46
323	Managing alcohol withdrawal in hospitalized patients. 2007 , 20, 20-5		11
322	Identification of neurotransmitter receptor genes involved in alcohol self-administration in the rat prefrontal cortex, hippocampus and amygdala. 2007 , 31, 53-64		20
321	The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. 2007 , 52, 1555-62		56

320 The Reply. **2007**, 120, e11

319 Baclofen for alcoholism. **2007**, 370, 1884-5

18

318 Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. **2007**, 370, 1915-22

490

317 Baclofen as a craving-suppressing agent. *CNS Drugs*, **2007**, 21, 693

6.7 2

316 Few pharmacotherapies appear effective in the treatment of dual substance abuse and dependence. **2007**, 23, 13-15

315 Metabotropic GABA Receptors. **2007**,

1

314 Baclofen for binge eating: an open-label trial. **2007**, 40, 687-91

89

313 Growth hormone response to the GABA-B agonist baclofen in 3-week abstinent alcoholics. **2007**, 41, 551-6

3

312 CGP7930: a positive allosteric modulator of the GABAB receptor. **2007**, 13, 308-16

38

311 The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. **2007**, 31, 11-8

172

310 Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. **2007**, 31, 582-95

44

309 Preclinical and clinical pharmacology of alcohol dependence. **2007**, 21, 9-28

33

308 Baclofen alters flash-evoked potentials in Long-Evans rats. **2007**, 86, 727-40

1

307 Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety. *Psychopharmacology*, **2007**, 190, 541-53

4.7 63

306 Reducing effect of the positive allosteric modulator of the GABA(B) receptor, GS39,783, on alcohol self-administration in alcohol-preferring rats. *Psychopharmacology*, **2007**, 193, 171-8

4.7 49

305 5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation. **2008**, 16, 7983-91

30

304 Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. **2008**, 42, 375-81

31

303 Neuropharmacology of alcohol addiction. **2008**, 154, 299-315

389

302	Insulin but not insulin growth factor-1 correlates with craving in currently drinking alcohol-dependent patients. 2008 , 32, 450-8	42
301	Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABAB receptor, GS39783--comparison with the effect of the GABAB receptor direct agonist, baclofen. 2008 , 32, 1558-64	59
300	Relationship between the hypothalamic-pituitary-thyroid axis and alcohol craving in alcohol-dependent patients: a longitudinal study. 2008 , 32, 2047-53	34
299	Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats. 2008 , 13, 326-36	40
298	Neurobiology of addiction. An integrative review. 2008 , 75, 266-322	276
297	Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. 2008 , 75, 34-56	215
296	GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk for alcohol dependence. 2008 , 42, 184-91	130
295	NGF plasma levels increase due to alcohol intoxication and decrease during withdrawal. 2008 , 33, 999-1003	19
294	Baclofen improves abstinence in alcoholic cirrhosis: Still better to come?. 2008 , 49, 1083-5	5
293	New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. 2008 , 32, 1106-17	73
292	Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats. 2008 , 95, 284-7	60
291	Reply to the Letter Are the Effects of Gamma-Hydroxybutyrate (GHB) Treatment Partly Physiological in Alcohol Dependence? by Olivier Ameisen. <i>American Journal of Drug and Alcohol Abuse</i> , 2008 , 34, 237-238	3-7
290	Understanding and treating alcohol craving and dependence: recent pharmacological and neuroendocrinological findings. <i>Alcohol and Alcoholism</i> , 2009 , 44, 341-52	3-5 25
289	Packages of care for alcohol use disorders in low- and middle-income countries. 2009 , 6, e1000170	70
288	Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. 2009 , 287-310	3
287	Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. 2009 , 23, 883-90	30
286	Is cortisol involved in the alcohol-related fat mass impairment? A longitudinal clinical study. <i>Alcohol and Alcoholism</i> , 2009 , 44, 211-5	3-5 17
285	A selective ALDH-2 inhibitor reduces anxiety in rats. 2009 , 94, 255-61	23

284	Review article: the diagnosis and management of alcoholic hepatitis. 2009 , 30, 3-13		26
283	Development of pharmacotherapies for drug addiction: a Rosetta stone approach. 2009 , 8, 500-15		118
282	Complementary and alternative medicine in the treatment of substance use disorders--a review of the evidence. 2009 , 28, 292-300		17
281	Acute interaction of baclofen in combination with alcohol in heavy social drinkers. 2009 , 33, 19-30		68
280	Understanding and treating patients with alcoholic cirrhosis: an update. 2009 , 33, 1136-44		20
279	Operant behavior and alcohol levels in blood and brain of alcohol-dependent rats. 2009 , 33, 2113-23		95
278	Neurobiological mechanisms contributing to alcohol-stress-anxiety interactions. 2009 , 43, 509-19		54
277	Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. 2009 , 43, 555-8		63
276	Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. 2009 , 43, 559-63		40
275	The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. 2009 , 103, 30-6		91
274	Differential effects of GABAB autoreceptor activation on ethanol potentiation of local and lateral paracapsular GABAergic synapses in the rat basolateral amygdala. 2009 , 56, 886-95		24
273	Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. 2009 , 89, 193-219		55
272	Complete suppression of craving in alcohol-dependent individuals: is it possible?. <i>CNS Drugs</i> , 2009 , 23, 361-7	6.7	3
271	Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. <i>European Neuropsychopharmacology</i> , 2009 , 19, 487-98	1.2	55
270	Pharmacotherapy of addictive disorders. 2009 , 32, 277-89		36
269	Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. 2010 , 34, 1849-57		213
268	Psychosocial findings in alcohol-dependent patients before and after three months of total alcohol abstinence. <i>Frontiers in Psychiatry</i> , 2010 , 1, 17	5	3
267	GABAB receptors in addiction and its treatment. 2010 , 58, 373-96		71

266	Identifying quantitative trait loci (QTLs) and genes (QTGs) for alcohol-related phenotypes in mice. 2010 , 91, 173-204		17
265	Anticonvulsants for alcohol withdrawal. 2010 , CD005064		61
264	Emerging drugs to treat alcoholism. 2010 , 15, 695-711		23
263	Pharmacotherapies for adolescent substance use disorders. 2010 , 19, 591-608		16
262	GABAB receptors in reward processes. 2010 , 58, 315-71		88
261	Chemistry and pharmacology of GABAB receptor ligands. 2010 , 58, 19-62		95
260	Baclofen enhances extinction of opiate conditioned place preference. 2010 , 207, 353-9		46
259	Novel pharmacological approaches to drug abuse treatment. <i>Current Topics in Behavioral Neurosciences</i> , 2010 , 3, 343-86	3-4	10
258	Repetitive transcranial magnetic stimulation and drug addiction. 2011 , 23, 454-66		57
257	Fecal calprotectin concentrations in alcoholic patients: a longitudinal study. 2011 , 23, 76-80		4
256	Baclofen for alcohol withdrawal. 2011 , CD008502		14
255	Addressing the needs of older people with co-morbid alcohol and mental health disorders: a case series from a London Community Mental Health Team (CMHT). 2011 , 4, 8-16		2
254	The GABA-B positive modulator GS39783 decreases psychostimulant conditioned-reinforcement and conditioned-reward. 2011 , 16, 416-27		22
253	Response to Ameisen. 2011 , 35, 847-847		
252	Ethanol-enhanced GABA release: a focus on G protein-coupled receptors. 2011 , 65, 113-23		63
251	Growth hormone responses to GABAB receptor challenge with baclofen and impulsivity in healthy control and personality disorder subjects. <i>Psychopharmacology</i> , 2011 , 215, 41-8	4-7	8
250	Is baclofen effectief bij de behandeling van alcoholafhankelijkheid?. 2011 , 54, 218-218		
249	Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. 2011 , 6, 469-74		41

248	Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking. 2011 , 45, 33-44		40
247	Response to Ameisen. <i>Alcohol and Alcoholism</i> , 2011 , 46, 504-505	3.5	1
246	Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. <i>Alcohol and Alcoholism</i> , 2011 , 46, 714-20	3.5	42
245	Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Alcohol and Alcoholism</i> , 2011 , 46, 312-7	3.5	146
244	Substitution therapy for alcoholism: time for a reappraisal?. 2012 , 26, 205-12		53
243	High-dose baclofen for treatment-resistant alcohol dependence. 2012 , 32, 266-8		48
242	Abstinence and 'low-risk' consumption 1 year after the initiation of high-dose baclofen: a retrospective study among 'high-risk' drinkers. <i>Alcohol and Alcoholism</i> , 2012 , 47, 439-42	3.5	66
241	Pharmacotherapy of alcohol use disorders and concurrent psychiatric disorders: a review. 2012 , 57, 342-9		14
240	Comparison of the effect of the GABA α receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats. 2012 , 36, 1748-66		60
239	Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. <i>CNS Drugs</i> , 2012 , 26, 69-78	6.7	38
238	Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates. <i>Substance Abuse</i> , 2012 , 33, 336-49	3.8	32
237	Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. 2012 , 62, 2480-8		24
236	Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. 2012 , 37, 561-4		55
235	Dihydrocodeine/Agonists for alcohol dependents. <i>Frontiers in Psychiatry</i> , 2012 , 3, 21	5	2
234	Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. <i>Frontiers in Psychiatry</i> , 2012 , 3, 103	5	63
233	Histamine h3 receptor: a novel therapeutic target in alcohol dependence?. 2012 , 6, 36		10
232	Evidence-based pharmacotherapy of nicotine and alcohol dependence. 214-234		
231	A possible role of a cerebral energy gene in alcoholism. 2012 , 11, 404-11		

230	Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. 2012 , 100, 530-7		11
229	A transcriptional study in mice with different ethanol-drinking profiles: possible involvement of the GABA(B) receptor. 2012 , 102, 224-32		17
228	Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. <i>Psychopharmacology</i> , 2012 , 220, 87-96	4.7	25
227	Management of alcohol dependence in patients with liver disease. <i>CNS Drugs</i> , 2013 , 27, 287-99	6.7	66
226	Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. 2013 , 37, 1601-8		115
225	A human laboratory pilot study with baclofen in alcoholic individuals. 2013 , 103, 784-91		58
224	The effectiveness of pharmacological approaches in the treatment of alcohol withdrawal syndrome (AWS): a literature review. 2013 , 20, 601-12		6
223	Pharmacotherapy for alcohol dependence: status of current treatments. 2013 , 23, 692-9		78
222	Craving Typology Questionnaire (CTQ): a scale for alcohol craving in normal controls and alcoholics. 2013 , 54, 925-32		30
221	Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. 2013 , 133, 15-29		36
220	The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. 2013 , 36, 348-55		25
219	Neuroimaging as a Biomarker for the Diagnosis, Progression, and Treatment of Substance Abuse Disorders. 2013 , 281-305		
218	Baclofen for alcohol withdrawal. 2013 , CD008502		8
217	GABAB receptor activation attenuates the stimulant but not mesolimbic dopamine response to ethanol in FAST mice. 2013 , 237, 49-58		3
216	GABA-based evaluation of neurologic conditions: MR spectroscopy. 2013 , 34, 259-65		63
215	Baclofen and risperidone association increases dramatically triglycerides level. <i>Alcohol and Alcoholism</i> , 2013 , 48, 515-6	3.5	5
214	Efficacy and tolerability of baclofen in substance use disorders: a systematic review. 2013 , 19, 325-45		34
213	Increased Ethanol Consumption Following Chronic Psychosocial Stress: Do Oxytocin and Baclofen Hold any Therapeutic Promise?. <i>Frontiers in Psychiatry</i> , 2013 , 4, 148	5	3

212	Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. 2013 , 5, 99-107		17
211	Pharmacological Approaches to the Treatment of Alcohol Dependence in the Young. 2014 , 271-307		
210	GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. 2014 , 8, 140		67
209	Intra-nucleus accumbens shell injections of R(+)- and S(-)-baclofen bidirectionally alter binge-like ethanol, but not saccharin, intake in C57Bl/6J mice. 2014 , 272, 238-47		28
208	Neurobiologie der Alkoholabhängigkeit – Implikationen für die Pharmakotherapie. 2014 , 15, 36-43		
207	Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. <i>Alcohol and Alcoholism</i> , 2014 , 49, 453-6	3.5	36
206	Current pharmacological treatment approaches for alcohol dependence. 2014 , 15, 471-81		50
205	Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. 2014 , 46, 372-7		9
204	Gamma-aminobutyric acid system genes--no evidence for a role in alcohol use and abuse in a community-based sample. 2014 , 38, 938-47		12
203	Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study. 2014 , 114, 360-4		23
202	Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature. 2014 , 77, 242-52		13
201	Baclofen in the management of cannabis dependence syndrome. 2014 , 4, 50-2		9
200	Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment. 2014 , 5, 1-12		20
199	Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. <i>European Neuropsychopharmacology</i> , 2014 , 24, 181-91	1.2	22
198	Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice. <i>Psychopharmacology</i> , 2014 , 231, 333-43	4.7	33
197	Pharmacological approaches to reducing craving in patients with alcohol use disorders. <i>CNS Drugs</i> , 2014 , 28, 343-60	6.7	48
196	Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. <i>Alcohol and Alcoholism</i> , 2014 , 49, 654-60	3.5	69
195	Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile. 2014 , 171, 4941-54		18

194	Neurocircuitry of alcohol addiction: synthesis from animal models. 2014 , 125, 33-54		125
193	Molecular basis of alcoholism. 2014 , 125, 89-111		44
192	Can cannabis be considered a substitute medication for alcohol?. <i>Alcohol and Alcoholism</i> , 2014 , 49, 292-83.5		29
191	Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns--a cohort study. <i>European Neuropsychopharmacology</i> , 2014 , 24, 192-9	1.2	34
190	Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study. 2014 , 39, 434-8		7
189	Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons. 2014 , 19, 16-26		18
188	Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials. 2014 , 69, 427-35		13
187	[Use in France of Baclofen for Alcohol Dependence from 2007 to 2013: Cohort Study Based on the Databases SNIIRAM and PMSI]. 2015 , 70, 443-53		22
186	Treatment of binge eating disorder with high-dose baclofen: a case series. 2015 , 35, 357-9		6
185	Anticraving Effect of Baclofen in Alcohol-Dependent Patients. 2015 , 39, 1602-8		30
184	Baclofen as relapse prevention in the treatment of gamma-hydroxybutyrate dependence: a case series. 2015 , 35, 313-8		9
183	Baclofen for alcohol withdrawal. 2015 , CD008502		15
182	Baclofen as an anti-craving agent for adolescent inhalant dependence syndrome. 2015 , 34, 696-7		2
181	Alcohol and violence: neuropeptidergic modulation of monoamine systems. 2015 , 1349, 96-118		40
180	Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence. <i>World Journal of Gastroenterology</i> , 2015 , 21, 8516-26	5.6	6
179	Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond. 2015 , 9, VE01-VE07		34
178	Advances in alcoholic liver disease: An update on alcoholic hepatitis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11893-903	5.6	18
177	Tolerability of High-dose Baclofen in the Treatment of Patients with Alcohol Disorders: A Retrospective Study. <i>Alcohol and Alcoholism</i> , 2015 , 50, 551-7	3.5	28

176	Effacer l'app�ence pour l'alcool. [Propos de « Vrit� et mensonges sur le Baclof�e. La gu�ison de l'alcoolisme », entretien de Renaud de Beaurepaire avec Claude Servan-Schreiber. 2015 , 80, 230-232		
175	Identification and management of alcohol withdrawal syndrome. <i>Drugs</i> , 2015 , 75, 353-65	12.1	87
174	High doses of Baclofen as suicide attempt in patients with alcohol use disorders - A serious concern. 2015 , 17, 99-100		11
173	Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. 2015 , 10, 6		1
172	Baclofen as relapse prevention in the treatment of Gamma- Hydroxybutyrate (GHB) dependence: an open label study. 2015 , 15, 91		14
171	Tailored dose baclofen in patients with alcoholic liver disease: A case series with 2-year follow-up of hospitalisation. 2015 , 23, 510-517		6
170	Pharmacotherapy for alcohol use disorder: current and emerging therapies. 2015 , 23, 122-33		38
169	High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2015 , 25, 1167-77	1.2	126
168	Are gamma amino acids promising tools of crystal engineering? [Multicomponent crystals of baclofen. <i>CrystEngComm</i> , 2015 , 17, 8264-8272	3.3	10
167	Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. 2015 , 52, 24-30		61
166	A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. <i>Psychopharmacology</i> , 2015 , 232, 233-43	4.7	32
165	[Baclofen: Innovative treatment or French controversy?]. 2015 , 36, 3-6		2
164	R(+)-Baclofen, but Not S(-)-Baclofen, Alters Alcohol Self-Administration in Alcohol-Preferring Rats. <i>Frontiers in Psychiatry</i> , 2016 , 7, 68	5	16
163	Pharmacotherapy of alcoholic liver disease in clinical practice. 2016 , 70, 119-31		19
162	Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. 2017 , 16, 125-132		4
161	Baclofen: Therapeutic Use and Potential of the Prototypic GABAB Receptor Agonist. 2016 , 337-356		4
160	Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. 2016 , 39, 627-45		38
159	[The baclofene saga and the paradigm shift in alcohol addiction treatment]. 2016 , 45, 1117-1123		1

158	Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety. <i>Substance Abuse</i> , 2016 , 37, 286-98	3.8	63
157	Treatment of alcohol use disorders in patients with alcoholic liver disease. 2016 , 65, 618-30		105
156	Creating a new problem: The use of baclofen in the management of alcohol use disorder. 2016 , 35, 115-116		4
155	Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1950-1959	1.2	99
154	Alcohol use disorders in Australia. 2016 , 46, 1259-1268		12
153	Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. 2016 , 70, 148-61		23
152	Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. 2016 , 65, 269-87		26
151	Pharmacologie du baclofène et utilisation chez le patient alcoolodépendant. Une mise au point à l'usage du clinicien. 2016 , 51, 189-196		
150	Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. 2017 , 22, 581-615		41
149	Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. 2017 , 45, 865-882		48
148	Baclofen for alcohol use disorder. 2017 ,		2
147	Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013. 2017 , 55, 275-284		33
146	The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. <i>Addiction</i> , 2017 , 112, 1173-1183	4.6	42
145	A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. 2017 , 62, 11-15		12
144	Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. 2017 , 7, e1108		34
143	A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study. <i>Alcohol and Alcoholism</i> , 2017 , 52, 439-446	3.5	84
142	The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study. <i>Human Psychopharmacology</i> , 2017 , 32, e2593	2.3	9
141	The GABA Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats. <i>Neuropsychopharmacology</i> , 2017 , 42, 1789-1799	8.7	38

140	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. 2017 , 18, 86-119		38
139	Baclofen for alcohol withdrawal. 2017 , 8, CD008502		13
138	Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. <i>European Neuropsychopharmacology</i> , 2017 , 27, 1077-1089	1.2	13
137	Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons. 2017 , 179, 47-54		10
136	One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. 2017 , 29, 1155-1160		16
135	KCTD12 modulation of GABA(B) receptor function. 2017 , 5, e00319		10
134	How good are publicly available web services that predict bioactivity profiles for drug repurposing?. 2017 , 28, 843-862		32
133	Pharmacotherapy of alcoholism - an update on approved and off-label medications. 2017 , 18, 1187-1199		60
132	Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. <i>American Journal of Drug and Alcohol Abuse</i> , 2017 , 43, 324-331	3.7	19
131	Targeted intervention: Computational approaches to elucidate and predict relapse in alcoholism. 2017 , 151, 33-44		22
130	The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABA receptor with a potential for treatment of anxiety, pain and spasticity. 2017 , 114, 34-47		17
129	Advances in Pharmacotherapy Development: Human Clinical Studies. <i>Handbook of Experimental Pharmacology</i> , 2018 , 248, 579-613	3.2	15
128	Speaking fluently with baclofen?. 2017 , 2017,		3
127	Baclofen Overdose Presenting as Psychosis with Catatonia. 2017 , 39, 695-697		6
126	: An Emergent Model for Delineating Interactions between the Circadian Clock and Drugs of Abuse. 2017 , 2017, 4723836		1
125	Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. <i>Addiction</i> , 2018 , 113, 1396-1406	4.6	87
124	Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial. <i>CNS Drugs</i> , 2018 , 32, 437-442	6.7	14
123	Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment. 2018 , 137, 230-239		6

122	An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with versus without chronic pretreatment with high dosage baclofen. 2018 , 32, 198-199		0
121	Advancing Pharmacotherapy Development from Preclinical Animal Studies. <i>Handbook of Experimental Pharmacology</i> , 2018 , 248, 537-578	3.2	8
120	Digitization of multistep organic synthesis in reactionware for on-demand pharmaceuticals. 2018 , 359, 314-319		117
119	Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. 2018 , 212, 362-369		55
118	Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. 2018 , 133, 65-76		21
117	New steps for treating alcohol use disorder. <i>Psychopharmacology</i> , 2018 , 235, 1759-1773	4.7	22
116	Inhibition of Glyoxalase 1 reduces alcohol self-administration in dependent and nondependent rats. 2018 , 167, 36-41		5
115	Microinjection of baclofen and CGP7930 into the ventral tegmental area suppresses alcohol self-administration in alcohol-preferring rats. 2018 , 136, 146-158		15
114	LC-MS/MS method for quantification of baclofen in hair: A useful tool to assess compliance in alcohol dependent patients?. 2018 , 10, 694-700		7
113	Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. <i>Addiction</i> , 2018 , 113, 220-237	4.6	80
112	Alcohol Withdrawal Management and Relapse Prevention in Pregnancy. 2018 , 9, 32-41		
111	Baclofen for alcohol use disorder. 2018 , 11, CD012557		23
110	Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures. <i>Frontiers in Psychiatry</i> , 2018 , 9, 664	5	6
109	How to Manage Self-Poisoning With Baclofen in Alcohol Use Disorder? Current Updates. <i>Frontiers in Psychiatry</i> , 2018 , 9, 417	5	7
108	A Review of the Potential Mechanisms of Action of Baclofen in Alcohol Use Disorder. <i>Frontiers in Psychiatry</i> , 2018 , 9, 506	5	17
107	Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165'334 patients between 2009 and 2015 in France. 2018 , 27, 1239-1248		24
106	Tailored-Dose Baclofen in the Management of Alcoholism: A Retrospective Study of 144 Outpatients Followed for 3 Years in a French General Practice. <i>Frontiers in Psychiatry</i> , 2018 , 9, 486	5	3
105	Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders. <i>Frontiers in Psychiatry</i> , 2018 , 9, 464	5	18

104	Risk factors, scoring systems, and interventions for alcohol relapse after liver transplantation for alcoholic liver disease. 2018 , 11, 105-110		13
103	Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2018 , 28, 795-806	1.2	98
102	Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder. <i>Frontiers in Psychiatry</i> , 2018 , 9, 385	5	6
101	Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking. <i>Frontiers in Psychiatry</i> , 2018 , 9, 412	5	7
100	Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?. 2018 , 32, 867-875		6
99	Baclofen for alcohol use disorder-a systematic meta-analysis. 2018 , 138, 232-242		35
98	Repetitive transcranial magnetic stimulation: Re-wiring the alcoholic human brain. 2019 , 74, 113-124		6
97	Craving mildern. 2019 , 20, 42-47		
96	Resolution of Baclofenium Hydrogenomaleate By Using Preferential Crystallization. A First Case of Complete Solid Solution at High Temperature and a Large Miscibility Gap in the Solid State. 2019 , 19, 4793-4801		13
95	Baclofen for alcohol withdrawal. 2019 , 2019,		2
94	Baclofen but Not Diazepam Alleviates Alcohol-Seeking Behavior and Hypothalamic-Pituitary-Adrenal Axis Dysfunction in Stressed Withdrawn Mice. <i>Frontiers in Psychiatry</i> , 2019 , 10, 238	5	5
93	The GABAergic System of the Basolateral Nucleus of the Amygdaloid Complex of the Brain in Formation of Alcohol Dependence. 2019 , 49, 463-467		
92	Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 103, 384-398	0.8	11
91	Use of Baclofen in Alcohol Use Disorder: A Clinical Approach. 2019 , 623-632		1
90	Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. <i>Alcohol and Alcoholism</i> , 2019 , 54, 272-278	3.5	5
89	Psychiatrische Behandlung eines alkoholabhängigen Patienten mit Lebererkrankung im Endstadium. <i>Psychopraxis Neuropraxis</i> , 2019 , 22, 108-113	0.1	
88	P.446 Baclofen for alcohol use disorder: Mechanisms, results and safety. <i>European Neuropsychopharmacology</i> , 2019 , 29, S316	1.2	
87	Le baclofène dans le traitement du trouble de l'usage d'alcool : données cliniques. <i>Revue Francophone Des Laboratoires</i> , 2019 , 2019, 43-48	0	

86	Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies. <i>Handbook of Experimental Pharmacology</i> , 2020 , 258, 443-462	3.2	10
85	State-of-the-Art Treatment of Alcohol Use Disorder. 2019 , 123-135		
84	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018 , 9, 708	5	28
83	Potential of GABA Receptor Positive Allosteric Modulators in the Treatment of Alcohol Use Disorder. <i>CNS Drugs</i> , 2019 , 33, 107-123	6.7	23
82	State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2019 , 45, 124-140	3.7	42
81	The use of off-label medications in substance abuse treatment programs. <i>Substance Abuse</i> , 2020 , 41, 340-346	3.8	0
80	Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. <i>Neurotherapeutics</i> , 2020 , 17, 127-141	6.4	7
79	Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. <i>Addiction</i> , 2020 , 115, 1265-1276	4.6	9
78	Efficacy of pharmacotherapeutics for patients comorbid with alcohol use disorders and depressive symptoms-A bayesian network meta-analysis. <i>CNS Neuroscience and Therapeutics</i> , 2020 , 26, 1185-1197	6.8	5
77	Cryo-EM structures of inactive and active GABA receptor. <i>Cell Research</i> , 2020 , 30, 564-573	24.7	40
76	Identification of a G-Protein-Independent Activator of GIRK Channels. <i>Cell Reports</i> , 2020 , 31, 107770	10.6	13
75	Structural basis of the activation of a metabotropic GABA receptor. <i>Nature</i> , 2020 , 584, 298-303	50.4	49
74	Toxicological considerations in the prescription of baclofen for the treatment of substance use disorders. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 309-317	5.5	3
73	The Inpatient with Dual Diagnosis (Co-Occurring Disorder). 2020 , 142-161		
72	Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. <i>Human Psychopharmacology</i> , 2020 , 35, e2722	2.3	3
71	A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. <i>Molecular Psychiatry</i> , 2021 , 26, 545-555	15.1	13
70	Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. <i>Psychopharmacology</i> , 2021 , 238, 1291-1302	4.7	12
69	[Pharmacotherapy of alcohol withdrawal: update and new developments]. <i>Der Nervenarzt</i> , 2021 , 92, 57-65	0.5	3

68	Multicomponent crystals of baclofen with acids and bases: conformational flexibility and synthon versatility. <i>CrystEngComm</i> , 2021 , 23, 91-99	3.3	5
67	Alcohol Use Disorder: The Role of Medication in Recovery. <i>Alcohol Research: Current Reviews</i> , 2021 , 41, 07	6.8	6
66	Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder. <i>Alcohol and Alcoholism</i> , 2021 , 56, 139-148	3.5	7
65	High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. <i>European Neuropsychopharmacology</i> , 2021 , 46, 28-36	1.2	3
64	The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 125, 296-313	9	4
63	Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. <i>Neuropsychopharmacology</i> , 2021 , 46, 2250-2256	8.7	7
62	Effects of Chronic Alcohol Use Disorder on the Visual Tilt Illusion. <i>Frontiers in Psychiatry</i> , 2021 , 12, 647615		
61	Pharmakologische Rückfallprophylaxe der Alkoholabhängigkeit. <i>Nervenheilkunde</i> , 2021 , 40, 628-635	0.3	
60	Alcohol. 2021 , 1-377		
59	Baclofen: clinical data. 2005 , 171-180		1
58	Pharmacotherapy for Alcoholism and Some Related Psychiatric and Addictive Disorders: Scientific Basis and Clinical Findings. 2010 , 943-980		1
57	GABAB Receptor as a Potential Therapeutic Target. 2007 , 289-312		3
56	Targeting the GABAB Receptor for the Treatment of Alcohol Use Disorder. 2016 , 287-307		5
55	Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic. 2008 , 91-178		1
54	Alkohol. 2019 , 93-119		1
53	Baclofen zur Behandlung der Alkoholabhängigkeit. <i>Sucht</i> , 2010 , 56, 167-174	0.5	2
52	Cryo-EM structures of inactive and Gi-coupled GABAB heterodimer.		0
51	Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey. <i>PLoS ONE</i> , 2014 , 9, e98062	3.7	36

50	Colour Vision Impairment in Young Alcohol Consumers. <i>PLoS ONE</i> , 2015 , 10, e0140169	3.7	16
49	Effects of acute alcohol ingestion on eye movements and cognition: A double-blind, placebo-controlled study. <i>PLoS ONE</i> , 2017 , 12, e0186061	3.7	17
48	Therapy for alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2143-58	5.6	45
47	Baclofen for the treatment of alcohol dependence. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2012 , 50, 11-4	1.1	6
46	Baclofen in the management of inhalant withdrawal: a case series. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2008 , 10, 48-51		19
45	Clinical experience of baclofen in alcohol dependence: A chart review. <i>Industrial Psychiatry</i> , 2016 , 25, 11-16	0.9	7
44	Factors influencing adherence to anti-craving medications and drinking outcomes in patients with alcohol dependence: A hospital-based study. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2016 , 7, 72-9	0.2	8
43	Comparison between baclofen and topiramate in alcohol dependence: A prospective study. <i>Industrial Psychiatry</i> , 2019 , 28, 44-50	0.9	4
42	Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review. <i>Industrial Psychiatry</i> , 2018 , 27, 163-171	0.9	1
41	Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. <i>Indian Journal of Psychiatry</i> , 2019 , 61, 60-64	2.2	3
40	Risk factors and outcomes associated with alcohol relapse after liver transplantation. <i>World Journal of Hepatology</i> , 2017 , 9, 771-780	3.4	24
39	Practical outpatient pharmacotherapy for alcohol use disorder. <i>Drugs in Context</i> , 2018 , 7, 212308	5.2	14
38	Baclofen Abuse due to Its Hypomanic Effect in Patients with Alcohol Dependence and Comorbid Major Depressive Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017 , 15, 187-189	3.4	8
37	Brain Functional Magnetic Resonance Imaging Cue-reactivity Can Predict Baclofen Response in Alcohol Use Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018 , 16, 290-301	3.4	12
36	Pharmacotherapies for the Treatment of Alcohol Dependence: Current and on the Horizon. 2007 , 123-143		
35	[Baclofen for alcohol addiction]. <i>Tidsskrift for Den Norske Laegeforening</i> , 2011 , 131, 2132-3	3.5	
34	Alcohol Use Disorders. 2011 , 1091-1104		
33	Vraies et fausses innovations en psychiatrie. 2012 , 125-143		

32	Alcohol. 2012 , 123-136			1
31	Farmakoterapia wspomagajāca w leczeniu uzaleŹnienia od alkoholu i narkotykw. 2013 ,			
30	Therapie Psychischer Erkrankungen - Pages 1-91. 2014 , 1-91			
29	Therapie Psychischer Erkrankungen - Pages e1-e96. 2015 , e1-e96			
28	Drugs to Treat Alcohol Dependence-A Perspective. <i>Journal of Addiction and Dependence</i> , 2016 , 2,			1
27	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. 2017 , 1-111			
26	Le baclofēe est-il efficace dans le traitement de l'alcoolisme ? Etude Bacloville. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2017 , 201, 1349-1359		0.1	
25	Baclofen as Anti-Craving Agent against Several Addiction. <i>International Journal of Complementary & Alternative Medicine</i> , 2017 , 9,		0.5	0
24	Inhibition of Glyoxalase 1 reduces alcohol self-administration in dependent and nondependent rats.			
23	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. 2019 , 1-119			
22	Baclofen and naltrexone, but not N-acetylcysteine, affect voluntary alcohol drinking in rats regardless of individual levels of alcohol intake. <i>Behavioural Pharmacology</i> , 2021 , 32, 251-257		2.4	3
21	GABAB Receptors and Alcohol Use Disorders: Clinical Studies. <i>Current Topics in Behavioral Neurosciences</i> , 2021 , 1		3.4	3
20	Pharmacotherapy of Alcohol Use Disorders. 2020 , 1-17			
19	Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. <i>Alcohol Research</i> , 2008 , 31, 400-7			6
18	Focus on: Neuroscience and treatment: the potential of neuroscience to inform treatment. <i>Alcohol Research</i> , 2010 , 33, 144-51			3
17	Pharmacotherapy of alcohol use disorders: seventy-five years of progress. <i>Journal of Studies on Alcohol and Drugs Supplement</i> , 2014 , 75 Suppl 17, 79-88		3.9	44
16	Treatment of alcohol use disorder in patients with liver disease.. <i>Current Opinion in Pharmacology</i> , 2022 , 62, 145-151		5.1	0
15	Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.. <i>Drugs</i> , 2022 ,		12.1	8

14	Treating Alcohol Use Disorder in Patients with Alcohol Associated Liver Disease.. <i>Seminars in Liver Disease</i> , 2022 ,	7.3	○
13	Specialist treatment. 197-217		
12	The inpatient with dual diagnosis. 113-129		
11	Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	○
10	Preventive Effects of Baclofen but Not Diazepam on Hippocampal Memory and Glucocorticoid Alterations After Prolonged Alcohol Withdrawal in Mice. <i>Frontiers in Psychiatry</i> , 2022 , 13,	5	
9	Baclofen (fun drug) and ethanol combined poisoning in humans: A histopathology and morphometry model. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2022 , 90, 102373	1.7	
8	Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. 13,		○
7	Baclofen in alcohol use disorder: An analysis of the data provided by the French Temporary Recommendation for Use 2014-2017 cohort. 13,		○
6	FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment: a pharmacokinetic-pharmacodynamic study. 2022 , 23,		○
5	Bayesian Pharmacometrics Analysis of Baclofen for Alcohol Use Disorder.		○
4	Pharmacotherapy of Alcohol Use Disorders. 2022 , 4303-4319		○
3	Effects of baclofen on insular gain anticipation in alcohol-dependent patients: a randomized, placebo-controlled, pharmaco-fMRI pilot trial.		○
2	Baclofen for alcohol use disorder. 2023 , 2023,		○
1	Pharmacotherapy options for alcohol use disorder in patients with alcohol-associated liver disease: a brief guide for clinicians. Publish Ahead of Print,		○